Living up to our name.
Uniquely Differentiated. Fast. Energetic.
Our name – Cabaletta – is derived from the operatic term for the second part of an aria that is designed to highlight the technical expertise of the lead singer. While our company is not the first to develop chimeric T cells as therapeutics, we are the first to develop them in a way that leverages the potential of T cells to specifically eliminate only B cells that cause autoimmune disease while sparing the healthy B cells. Because we stand on the shoulders of giants with the core technology, leveraging the work of our founding scientists, we also expect to advance our portfolio with a rapid and repetitive rhythm, similar to the rhythm that is typical of a cabaletta. If you want to be part of the next generation in cell therapy for autoimmune diseases, come make history with us. Contact us at firstname.lastname@example.org.